In addition, the pharmacological and genetic inhibition of p38 MAPK reduced the levels of many NRF2 targets, such as NQO1 and HO1, and increased the sensitivity of tumor cells to treatment with TMZ [66]. This evidence concerns the gene NFE2L2 and neoplasm.